Summary
The AI-generated list makes numerous claims about fatigue incidence, timing, mechanisms, dosing correlations, comorbid conditions, resolution, and comparisons across other drugs, but the provided FDA label excerpts concern only thyroid C-cell tumor risk/MTC contraindication. None of the fatigue-related claims are supported or verifiable against the supplied label text, and several include quantitative and mechanistic details not present in the provided sections.
Category Scores
Accurate Statements
OZEMPIC is described as a GLP-1 receptor agonist that affects blood sugar regulation.
Not supported by the provided label excerpts (only thyroid C-cell tumor risk/contraindications/adverse reactions seriousness are included).
Unsupported Statements
Fatigue is reported as a side effect of Ozempic (semaglutide).
The provided label excerpts do not list fatigue as an adverse reaction.
In clinical trials and post-marketing data, fatigue affects 1-11% of users.
No fatigue incidence/range is provided in the supplied label excerpts.
Fatigue may be described as tiredness, asthenia, or general weakness.
No terminology/mapping for fatigue is present in the provided label excerpts.
Fatigue is more common during the first weeks of Ozempic treatment as the body adjusts.
No timing/incidence-by-treatment-duration information for fatigue is present in the provided label excerpts.
Fatigue occurs in up to 11% of patients in trials.
No trial incidence data for fatigue is present in the provided label excerpts.
Fatigue typically starts early in treatment and may resolve with time or dose adjustment.
No such course/resolution/dose-adjustment information for fatigue is present in the provided label excerpts.
Higher doses of Ozempic (1-2 mg weekly) correlate with increased reports of fatigue compared to lower doses (0.25-0.5 mg).
No dose-stratified fatigue reporting is present in the provided label excerpts.
Dehydration from nausea, vomiting, or diarrhea is listed as a mechanism that can lead to fatigue.
No mechanistic explanation linking dehydration/GI adverse reactions to fatigue is present in the provided label excerpts.
Nausea/vomiting/diarrhea is described as common in 15-20% of users.
No nausea/vomiting/diarrhea incidence is present in the provided label excerpts.
Low blood sugar (hypoglycemia) is associated with Ozempic, especially when combined with insulin or sulfonylureas.
No hypoglycemia-related statements or interaction/cose-therapy information is present in the provided label excerpts.
Calorie restriction from appetite suppression is described as a mechanism that can lead to fatigue.
No appetite suppression/calorie restriction mechanism is present in the provided label excerpts.
Fatigue is described as rarely due to direct effects on the central nervous system or thyroid function.
No CNS or thyroid-function attribution for fatigue is present in the provided label excerpts.
Fatigue may be accompanied by symptoms such as brain fog or muscle weakness (as reported by users).
No symptom complex for fatigue, and no 'as reported by users' content, is present in the provided label excerpts.
Fatigue may improve after 4-6 weeks (as described in the text).
No 4–6 week improvement timeframe is present in the provided label excerpts.
Persistent fatigue beyond 8 weeks warrants medical review.
No label guidance on when fatigue warrants review is present in the provided label excerpts.
Persistent fatigue beyond 8 weeks could indicate anemia, sleep apnea, or gallbladder problems.
No label differential diagnosis guidance for fatigue is present in the provided label excerpts.
Gallbladder problems are described as occurring in 1-2% of users.
No gallbladder incidence is present in the provided label excerpts.
Stopping Ozempic usually resolves it quickly (as stated in the text).
No label statement about rapid resolution after stopping for fatigue is present in the provided label excerpts.
Ozempic is described as causing fatigue that is mostly transient and fades within 1-4 weeks as tolerance builds.
No label statement about tolerance build or 1–4 week fade for fatigue is present in the provided label excerpts.
Ozempic fatigue may require medical evaluation if severe, sudden, or associated with dizziness, rapid heartbeat, confusion, or weight loss >5% unintended.
No label linkage between fatigue severity/specific accompanying symptoms/weight loss threshold and evaluation is present in the provided label excerpts.
Severe or associated symptoms could indicate pancreatitis, thyroid issues, or an allergic reaction (rare, <1%).
No such clinical interpretation for fatigue, and no <1% allergic reaction statistic, is present in the provided label excerpts.
Switching GLP-1 drugs resolves fatigue for some patients (as stated in the text).
No label statement about switching GLP-1 drugs to resolve fatigue is present in the provided label excerpts.
Fatigue rates are described as similar between Ozempic (same drug as Wegovy) and Trulicity (dulaglutide).
No comparative fatigue incidence across semaglutide brands or across dulaglutide is present in the provided label excerpts.
Fatigue rates are described as slightly higher than Mounjaro (tirzepatide) in head-to-head data.
No head-to-head comparative data for fatigue vs tirzepatide is present in the provided label excerpts.
Contradictions
Low
AI Statement
OZEMPIC is described as causing fatigue that is mostly transient and fades within 1-4 weeks as tolerance builds.
Label Reference
Provided label excerpts do not address fatigue course/tolerance; therefore no direct contradiction can be confirmed from the supplied text.
Important Omissions
The AI response does not address the supplied label’s thyroid C-cell tumor risk/contraindication requirements (personal/family history of MTC or MEN 2, and the warning about symptoms and calcitonin/ultrasound monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided evaluation cannot confirm that fatigue-related content is label-accurate; however, the supplied label excerpts focus on thyroid C-cell tumor risk and do not directly connect the fatigue assertions to label safety guidance. The main risk here is misinformation/incorrect emphasis rather than a direct contradiction of MTC/MEN 2 contraindications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Fatigue and related quantitative/mechanistic/comparative claims are not supported by the supplied FDA label excerpts (which contain thyroid C-cell tumor risk/contraindications only).
Suggested Improvement
Limit claims strictly to the provided label-supported sections. For example, if auditing for the thyroid C-cell tumor risk, discuss the MTC/MEN 2 contraindication and counseling/monitoring statements from Sections 4 and 5.1; avoid or remove fatigue incidence, timing, mechanisms, severity guidance, and cross-drug comparisons unless the full adverse reactions sections are provided.